BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

New Data Validates TAP Biosystems' Micro Bioreactor as Realistic Scale-Down Model Peer-Reviewed Paper Shows Matched Performance Between Ambr and 2L Bioreactors


5/8/2012 11:31:46 AM

08 May 2012 -- TAP Biosystems, a leading supplier of innovative cell culture systems and consumables for life science applications, today announced that a peer reviewed paper authored by scientists at a leading US biopharmaceutical company, has demonstrated that the advanced micro bioreactor system (ambr™) system is equivalent in performance to a 2L bioreactor, showing that ambr is a realistic scale-down model.

The ambr system, which closely replicates the characteristics of bioreactors at micro scale, was tested in a fed-batch process with four recombinant Chinese Hamster Ovary (CHO) cell lines expressing antibodies. The clones were grown in parallel in ambr, shake flasks and 2L benchtop bioreactor to determine which technology provided the optimum scale-down model for their process development work. Their results showed that cultures grown in ambr matched those grown in a 2L bioreactor, in terms of controlling the environment and culture performance. However, cultures grown in shake flasks did not compare to those grown in either ambr or the 2L bioreactor.

This publication also indicated that using ambr reduced manual operations by automating many liquid handling and sampling functions. The paper stated that this increased the throughput and operational efficiency and ensured scientists at the company saved time using ambr compared to using a 2L bioreactor as a scale-down model to predict antibody expressing CHO cell performance in large scale bioreactors.

Dr Barney Zoro, ambr Product Manager at TAP Biosystems stated: "This paper highlights literature reports and provides clear evidence that, due to limitations in pH and DO control; shake flasks are a poor model for process scale-up. By contrast, ambr is shown to be an equivalent model to 2L bioreactors, with automation and single use technologies making ambr both easier and more time efficient for clone selection and scalable process development.”

Zoro concluded: “For CHO cell culture scientists focused on rapidly developing robust antibody production processes, the data confirms that using ambr as a scale-down model will provide them with a major competitive advantage.”

For further information, please contact:

Matthew Walker, Head of Communications

York Way, Royston, Hertfordshire, SG8 5WY, UK

Tel: +44 1763 227200 Fax: +44 1763 227201



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES